SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after reports surfaced of a potential partnership with Novo Nordisk to distribute GLP-1 obesity drugs, signaling an end to their prior legal dispute. This development has ignited fervent community discussion about a massive short squeeze due to the stock's high short interest and its strengthened position in the digital health market.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a surprise partnership announcement with Hims & Hers to distribute its obesity drugs, ending a prior feud. The community is actively discussing the substantial surge in Hims' stock compared to Novo Nordisk's more modest reaction, raising questions about the deal's implications for the GLP-1 market and competitive landscape.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is experiencing a sharp rebound, driven by the departure of a controversial FDA official, which the community speculates could pave an easier regulatory path for its Huntington's disease gene therapy and is currently fueling a short squeeze.

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Savara Inc

Savara is trending following the FDA's Day 74 Letter confirming MOLBREEVI's Biologics License Application is under full review with a PDUFA target action date of August 22, 2026, and no advisory committee meeting planned. The community sees this as a positive step towards Molbreevi becoming a first-in-class therapy for autoimmune PAP, fueling optimism around its market potential and future valuation.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals ($DAWN) is trending after agreeing to be acquired by Servier for $21.50 per share in cash, a deal valued at approximately $2.5 billion that offers a significant premium. The community is celebrating substantial gains, with many noting how patience and conviction paid off amidst previous buyout speculation and a recent massive volume spike.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as it announces a $300 million restructuring charge, fueling speculation among investors about a potential exit from its struggling Converse brand. The community remains divided, with many concerned about ongoing margin pressures and the slow pace of a turnaround, while others see a long-term buying opportunity despite confusing price action around recent tariff news.

Rithm Capital Corp. engages in the provision of real estate, credit, and financial services. It operates through the following segments: Origination and Servicing, Investment Portfolio, Residential Transitional Lending, Asset Management, and Corporate. The Origination and Servicing segment includes residential mortgage loans underlying mortgage servicing right assets as well as those sub-service for third parties. The Investment Portfolio segment consists of residential mortgage loans, SFR properties, consumer loans, Non-Agency RMBS, Excess MSRs and servicer advance investments. The Residential Transitional Lending segment competes for both experienced sponsors, including developers and investors in residential real estate, and attractive lending opportunities based on several factors. The Asset Management segment focuses on the wholly owned subsidiaries, Sculptor, and RCM Manager. The company was founded on September 26, 2011 and is headquartered in New York, NY.

Rithm Capital Corporation

Rithm Capital is actively discussed for its impending S&P SmallCap 600 index inclusion, which analysts anticipate will trigger substantial institutional buying, alongside its consistent earnings beats and strategic evolution into a diversified asset manager. The community is vigorously debating the stock's significant undervaluation and the potential for a future C-Corp conversion or spin-off to unlock considerable shareholder value.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is currently trending following strong Q4 earnings and optimistic 2026 revenue guidance, significantly bolstered by a key competitor's recent clinical setback in the Cushing's syndrome market; this fuels community discussions on Recorlev's blockbuster trajectory and XP-8121's Phase 3 progress despite ongoing market volatility.

Global X Funds - Global X Copper Miners ETF

Copper miners are rallying to new highs, fueled by escalating demand from AI, electrification, and defense sectors amidst a deepening structural supply deficit. The community is actively discussing copper as the next major commodity breakout, especially with new US tariffs aiming to bolster strategic critical mineral reserves.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


GSID
Goldman Sachs ETF Trust - Goldman Sachs MarketBeta International Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Latest GSID News

GSIDGoldman Sachs ETF Trust - Goldman Sachs MarketBeta International Equity ETF